“協和學(xué)者”特聘教授，北京協和醫(yī)學(xué)院準聘副教授，中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院病原生物(wù)學(xué)研究所課題組長(cháng)，國(guó)家衛健委病原系統生物(wù)學(xué)重點實驗室PI，病原體(tǐ)感染防控教育部重點實驗室PI。曾任北京市第十屆青年聯合會委員，中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院青年科(kē)學(xué)家創新(xīn)聯盟理(lǐ)事會副理(lǐ)事長(cháng)，中(zhōng)國(guó)青年科(kē)技(jì )工(gōng)作(zuò)者協會基礎專委會委員。哈爾濱工(gōng)業大學(xué)/哈爾濱醫(yī)科(kē)大學(xué)獲醫(yī)學(xué)遺傳學(xué)博士學(xué)位，美國(guó)匹茲堡大學(xué)傳染病學(xué)博士後，主要研究方向為(wèi)醫(yī)學(xué)病毒學(xué)。發現了HCV輔助受體(tǐ)Occludin、研發了高效廣譜的SARS-CoV-2中(zhōng)和抗體(tǐ)、深入闡明了HCV和ZIKV等多(duō)種病毒的感染與緻病機制、建立了多(duō)維度抗病毒藥物(wù)研究平台等。教育部自然科(kē)學(xué)獎二等獎第一完成人。作(zuò)為(wèi)通訊作(zuò)者（含第一作(zuò)者）在《Hepatology》、《Sci Adv》、《Nat Commun》、《Signal Transduct Target Ther》、《Cancer Res》、《J Cell Biol》、《J Virol》等本領域高水平專業雜志(zhì)發表SCI論文(wén)40餘篇；超10項專利獲授權；完成新(xīn)冠病毒納米抗體(tǐ)成果轉化1項；作(zuò)為(wèi)項目負責人獲得國(guó)家重點研發計劃、863、973、國(guó)自然重點項目和面上項目等科(kē)研課題多(duō)項；培養研究生20餘名(míng)。

聚焦醫(yī)學(xué)病毒學(xué)基礎研究和抗病毒藥物(wù)研發，具(jù)體(tǐ)包括：
1.    病毒感染與緻病機制： 丙肝病毒的受體(tǐ)發現與感染機制研究、寨卡和登革等黃病毒的緻病機制與抗病毒研究等。
2.    抗體(tǐ)藥物(wù)研發：全合成抗體(tǐ)發現平台與AI抗體(tǐ)設計平台、抗感染與抗腫瘤抗體(tǐ)藥物(wù)研發等。

作(zuò)為(wèi)項目負責人主持“國(guó)家重點研發計劃”項目1項，“863” 項目1項，國(guó)家自然基金區(qū)域聯合基金重點項目1項、面上項目7項，醫(yī)科(kē)院創新(xīn)工(gōng)程項目1項等。作(zuò)為(wèi)課題負責人主持“973計劃”課題1項、“傳染病重大專項”課題1項等。參與其他(tā)國(guó)家級項目多(duō)項。

一、代表性論文(wén)
1. Yang X, Duan H, Liu X, Zhang X, Pan S, Zhang F, Gao P, Liu B, Yang J, Chi X, Yang W. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening. J Virol. 2023 Jul 27;97(7). 
2. Chi X, Zhang X, Pan S, Yu Y, Shi Y, Lin T, Duan H, Liu X, Chen W, Yang X, Chen L, Dong X, Ren L, Ding Q, Wang J, Yang W. An ultrapotent RBD-targeted biparatopic nanobodyneutralizes broad SARS-CoV-2 variants. Signal Transduct Target Ther.2022 Feb 9;7(1):44.
3. Lin T, Chi X, Liu X, Pan S, Chen W, Duan H, Zhang X, Yang W. Recombinant Full-Length Hepatitis CVirus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies. Front Immunol.2022 Jun 28;13:831285.
4. Zhou L, Zhou J, Chen T, Chi X, Liu X, Pan S, Chen W, Wu T, Lin T, Zhang X, Li YP, Yang W. Identification of Ascomycin against Zika virus infection through screening of natural product library. Antiviral Res. 2021 Dec;196:105210.
5. Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, Ren L, Jin Q, Wang J, Yang W. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020Sep 10;11(1):4528.
6. Ci Y, Liu ZY, Zhang NN, Niu Y, Yang Y, Xu C, Yang W, Qin CF, Shi L. Zika NS1-induced ER remodeling is essential for viral replication. J Cell Biol. 2020 Feb 3;219(2). 
7. Zhou J, Chi X, Cheng M, Huang X, Liu X, Fan J, Xu H, Lin T, Shi L, Qin C, Yang W. Zika virus degrades the ω-3fatty acid transporter Mfsd2a in brain microvascular endothelial cells and impairs lipid homeostasis. Sci Adv. 2019 Oct 23;5(10):eaax7142.
8. Xu H, Cheng M, Chi X, Liu X, Zhou J, Lin T, Yang W. High-Throughput Screening Identifies Mixed-Lineage Kinase 3 as a Key Host Regulatory Factor in Zika Virus Infection. J Virol. 2019Aug 28;93(18).
9. Fan J, Cheng M, Chi X, Liu X, Yang W. A Human Long Non-coding RNA LncATV Promotes Virus Replication Through Restricting RIG-I-Mediated Innate Immunity. Front Immunol. 2019 Jul 19;10:1711.
10. Cheng M, Niu Y, Fan J, Chi X, Liu X, Yang W. Interferon down-regulation of miR-1225-3p as an antiviral mechanism through modulating Grb2-associated binding protein 3 expression. J Biol Chem. 2018Apr 20;293(16):5975-5986.
11. Li D, Cheng M, Niu Y, Chi X, Liu X, Fan J, Fan H, Chang Y, Yang W. Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c. Int J Biol Sci. 2017 Feb 25;13(3):349-357.
12. Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F, Fan J, Li X, Jin Q, Zhong J, Li YP, Yang W. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep. 2016 Apr 28; 6:25224.
13. Li X, Niu Y, Cheng M, Chi X, Liu X, Yang W. AP1S3 is required for hepatitis C virus infection by stabilizing E2 protein. Antiviral Res. 2016 Jul; 131:26-34.
14. Yang W, Zhang M, Chi X, Liu X, Qin B, Cui S. An intramolecular bond at cluster of differentiation 81ectodomain is important for hepatitis C virus entry. FASEB J. 2015 Oct;29(10): 4214-26.
15. Niu Y, Si Y, Li Y, Chi X, Li X, Liu X, Li D, Cheng M, Fan J, Si S, Yang W. A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3. J Antimicrob Chemother. 2015 Jul; 70(7):2013-23.
16. Cheng M, Si Y, Niu Y, Liu X, Li X, Zhao J, Jin Q, Yang W. High-throughput profiling of alpha interferon- andinterleukin-28B-regulatedmicroRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol. 2013 Sep; 87(17):9707-18.
17. Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, LiX, Chen Y, Yang W. Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus ANS5A. J Virol. 2013 Feb; 87(3):1649-57.
18. Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. A humanclaudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology. 2012 Aug; 56(2):507-15.
19. Cheng M, Si Y, Yang Y, Liu X, Gong Q, Zhao J, Niu Y, Li X, Jin Q, Yang W. Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. J Antimicrob Chemother. 2012 May; 67(5):1080-7.
20. Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology. 2010 Mar1; 398(1):57-67.
21. Liu S#, Yang W#, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009 Feb; 83(4):2011-4.
22. Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, Conrads TP, Wang T. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008 Nov; 48(5):1396-403.
23. Yang W, Qiu C, Biswas N, Jin J, Watkins SC, Montelaro RC, Coyne CB, Wang T. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem. 2008 Mar 28; 283(13):8643-53.
24. Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J Biol Chem. 2007 Feb 9; 282(6):3799-808.
25. Yang W, Chen Y, Zhang Y, Wang X, Yang N, Zhu D. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Cancer Res. 2006 Feb 1; 66(3):1320-6.
二、科(kē)技(jì )獎勵
2017年，教育部自然科(kē)學(xué)獎二等獎，《丙型肝炎病毒複制機制與抗病毒研究》，第一完成人
三、成果轉化
2020年，新(xīn)冠病毒中(zhōng)和性納米抗體(tǐ)成果轉化。

已培養博士生畢業7人、碩士畢業生3人，聯合培養畢業生2人，大部分(fēn)畢業生在國(guó)家級科(kē)研院所和大學(xué)從事科(kē)研教學(xué)工(gōng)作(zuò)，部分(fēn)畢業生在海外學(xué)習或企業工(gōng)作(zuò)。在讀博士生5人，碩士生3人。